• Minicabecera4


 MG 2959 web

Euronext, the leading pan-European Exchange in the Eurozone, was present at BIOSPAIN, the largest biotechnology event organised by a national association of the sector in Europe, which took place in Seville from September 25 to 27. The exchange has launched its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs.

TechShare was launched in Paris in September and, for the first time, nine Spanish companies were selected to participate. Accompanied by Ability Pharma and Histocell, two of the Spanish biotechnology companies participating in the program, Susana de Antonio, director of Euronext in Spain, highlighted the "success" of this year's edition and the strength of the Spanish SME sector to strengthen its reputation international.

This fourth edition of the TechShare program has the presence of several leaders of the Spanish technological landscape, such as Fon, Anfix or Babel, as well as the telecommunications sector, such as CaseOnIt. In addition, these participants attended the first session in Paris with some leading biotechnology companies in the country, such as Ability Pharma, Minoryx Therapeutics, SOM Biotech and Histocell.


 MG 2959 web

The Basque biopharmaceutical company Histocell, belonging to the NorayBio Group, reinforces its internationalization strategy with the recent inauguration of its production plant in the Basque Country.

The entry of a new Japanese investment fund and the achievement of 6 new distribution agreements for REOXCARE internationally, are part of the firm commitment of the company to internationalisation, which allows marketing its products in the largest number of markets.

Capital increase with a Japanese investment fund

The company has also significantly increased its capital as the result of the entry of the Japanese investment fund Cell Innovation Partners that specializes in regenerative medicine and cell therapy and whose main partners are the Japanese company Reprocell and bank Shinsei. This is the first investment of this fund in a biopharmaceutical company in Spain. In this financing round, the main current partners of Histocell have also participated.


Histocell Factory Opening

Histocell has inaugurated its new production centre in Larrabetzu, dedicated to the manufacture of medical devices for regenerative medicine. The plant, which required an investment of 1.6 million euros and will initially generate 10 jobs and 30 additional jobs in the coming years, demonstrates the company's commitment to maintaining both its research and manufacturing activities in the Basque Country.


Histocell SPINE

Histocell and the pharmaceutical company Ferrer today announced that the first patients have been recruited for a Phase 1/2 clinical trial of FAB117-HC, a new cell therapy medicinal product for the treatment of acute spinal cord injuries of traumatic origin.

It is the first cellular medication designed to treat acute traumatic spinal cord injury, in the first 2-3 days after the accident, that has reached the clinical regulatory phase.

SPINE (Spinal acute Injury Neurosave Evaluation) is a Phase 1/2 clinical trial that evaluates the safety and preliminary efficacy of the drug in a total of 46 adult patients with acute traumatic spinal cord injury.